

JEFFREY GRANT KOENIG

ATTORNEY-AT-LAW



SUITE 760

THE ADDISON

831 E. MOREHEAD ST.

CHARLOTTE, NC 28202-2725

(704) 335-5471

reason for hope

The search for a preventive vaccine

by The AIDS Writers Group
Special to Q-Notes

President Clinton promised to make the development of a vaccine to prevent AIDS a major commitment of the government's scientific institutions. While most activists were disappointed that the promise didn't include ample funding, the announcement does point out some positive changes. The success of combination therapies has meant that activists have less fear that the successful development of a vaccine to prevent AIDS would mean decreased efforts in research aimed at treating and curing HIV disease. In addition, the announcement is a signal that many now believe that a preventive vaccine can be developed.

The idea behind vaccines

Vaccination is based upon an old observation: some people who get better after being struck with an illness don't get it again. Vaccines have a long history, going back thousands of years to the Chinese who gave dried out smallpox to uninfected people to lessen the chances of getting the disease later. Modern vaccines go back to Jenner and his introduction of cowpox as a smallpox vaccine in 1798.

All of our immune systems have a built in capacity to fight some germs (including a number of viruses) and the diseases they cause. In addition, the body's immune system has the ability to learn to recognize an unfamiliar germ as an enemy. However, it takes time for the body to learn to fight an illness it has never seen. The time it takes to recognize a new illness and learn how to fight it can be the crucial few days or weeks that makes the difference between a disease easily defeated and one that causes serious damage or even death. Teaching the body to recognize a germ as an enemy is what a vaccine does, so that when the body is exposed to the real germ, it will recognize and destroy it.

In HIV, the virus makes tens of billions of copies of itself in the first few days and weeks after infection. Therefore, the virus ends up infecting many parts of the body quickly. The hope is that a vaccine would get the immune system to attack so fast that the virus would not have a chance to reproduce and spread, and thereby HIV infection would be prevented.

Can a vaccine prevent AIDS?

Over the years, scientists have developed vaccines to fight many illnesses. However, some researchers believed that since the basis of a vaccine is getting the immune system to fight an invader, it might not be possible to develop an effective vaccine because, unlike other viruses, HIV attacks the immune system itself. In addition, it is feared that because there are so many varieties of HIV around the world, and the virus is able to mutate so quickly, a vaccine that recognized one strain of HIV might not recognize another.

Others argue that a vaccine is very possible. Among the reasons many believe this is so is the possibility that some small number of people are naturally immune to infection by HIV. If researchers can find out how their system's successfully fought off the virus, it might be possible to get other people's immune systems to do the same thing.

How a vaccine might work

For most diseases, the key to developing a vaccine is to look at people who have acquired a natural immunity to the disease or at people who have recovered from the disease. Researchers then look at the responses of those people's immune systems and attempt to find something that will create that response in others. As our knowledge of HIV disease increases, researchers are gradually learning what types of immune response won't work and what types may work to prevent HIV infection.

Creating a response is not difficult. After all, the body responds to the virus. The difficulty is creating the right response without infecting people. The safest vaccine is usually the weakest. For instance, one made up of small pieces of HIV could involve almost no risk of infection, but it might have the least chance of being effective. Vaccines more likely to work involve giving people a weakened (scientists call them "attenuated") live virus. Some individu-

als have somehow been infected with such a weakened virus and they have remained healthy for at least 12 years. Nevertheless, the safety of such a live-attenuated vaccine is not so clear. In some diseases, this kind of vaccine is used. The oral polio vaccine is such a live-attenuated vaccine, and about 8-10 people a year in the United States get polio from the vaccine. It's a price society is willing to pay to avoid thousands of cases if the vaccine was not used. However, until more is known about the safety of such a live HIV vaccine, the decision to use it will be difficult.

Over the past ten years, scientists have developed a number of HIV vaccines and it appears that many of them are safe. Some of them have been shown to protect chimps and other primates for at least one year. Unfortunately, these vaccines have not been tested on enough people to know if they work.

The time for trials

Clearly, more than in any other illness for which a vaccine has been developed, getting an AIDS vaccine will mean a lot of trial and error. More time, more money and more experiments with human candidates is the only way to determine if we are successful. The bad news is the research is not moving fast enough. Most of those vaccines which have moved beyond tests on animals and on to human testing, are in or have completed only the first phase of testing. These tests involve a very small number of people to ensure safety, without any results regarding effectiveness.

The good news is that one vaccine is ready to begin a later phase of testing, which will include people who were at high risk of getting infected with HIV, and therefore will look not only at whether they are safe, but also whether they are effective at preventing infection. The individuals involved are from HIVNET which recruits high-risk people, tries to teach safer behavior and also enrolls people into preventive trials. The vaccine is called ALVAC (from the fact it was designed in Albany, NY: "ALbany VACcine"). It will be tested in 14 sites across the country, involving 420 people. One-third of them will receive a placebo, one-third will get the ALVAC and one-third will get the ALVAC plus another vaccine known as GP-120 (which uses the non-active outer coating of the virus.) However, because infection rates are not that high in this country, the trial will take three years to complete, and it still isn't large enough to determine whether the vaccine works. If the results of this trial look promising, then a much larger and perhaps longer trial will be needed. Meanwhile, there are numerous other vaccines that have not had even the early safety tests, and many more which have had that first phase, but have not been approved for further testing.

A number of activists are frustrated at the slow response. To move the development of some HIV treatments, the tests after the initial safety tests are often rolled into one. Some activists believe something similar should be done for preventive AIDS vaccine trials. Individuals wishing to promote the development of a preventive vaccine may want to attend the National AIDS Vaccine Advocacy Forum to be held in San Diego, CA this November. For information, call the AIDS Vaccine Advocacy Coalition at (415) 248-1330.

A critical concern

While there is optimism about the possibility of developing a vaccine, there are also concerns. It will be years before any vaccine could be available and it may be much less than 100 percent effective. One of the questions that experts are struggling with is what the impact would be if there was a vaccine that lowered one's chances of getting the disease by 70 percent or 90 percent but didn't completely protect an individual. Given that possibility, a vaccine will be an added layer of protection, not an alternative to current prevention methods.

While there is testing of potential vaccines, no vaccine to date has been built which will stop the illness. It needs to be understood that practicing prevention through abstinence or safer sex should still be viewed as absolutely necessary. Even HIV-positive individuals need to protect themselves as well as their partners. HIV is not the only disease that is transmitted sexually and people with weaker immune systems face higher risks. In addition, there is the chance that one may contract a strain of the virus which is resistant to some antiviral drugs. Also, having a viral load which is undetectable does not mean that the virus cannot be transmitted. Vaccine or no vaccine — safe practices and protection are essential! ▼

Every Thursday day

Miss KITTY'S Play house

with Special guests every week...

September 25

Mid-Atlantic Entertainer of the Year '97-'98

Brittany Moore

with Miss Kitty and Our Fabulous House Cast

October 2

Sable Chanel

with Jasmine Perry and Miss Kitty

coming up... October 9

Miss Kitty's "House Cast Romp"

\$1.50 Drink & \$1.25 Beer Specials

\$3 Members \$5 Guests

MYTHOS

Uptown Charlotte • Corner of 6th & N. College • 704-375-8765 • www.mythosclub.com